Clinical Trials Browser

Lymphoma, Non-Hodgkin, HIV Infections, Lymphoma, Large B-Cell, Diffuse

NCT07052305 2026-04-09

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Phase 1 Recruiting

24 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT05757219 2026-03-31

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

Phase 2 Recruiting

27 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06043323 2026-03-12

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

Phase 2 Recruiting

20 enrolled

Lymphoid

Lymphoma, Follicular

NCT07042438 2026-03-05

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

Phase 2 Recruiting

56 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07188558 2026-03-04

PiNACLE-H2H

Phase 3 Recruiting

400 enrolled

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05633615 2026-02-02

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

396 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06213311 2026-01-14

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

Phase 2 Recruiting

40 enrolled

Lymphoid

Lymphoma, B-Cell

NCT07254754 2025-11-28

LATE-R-GEL-23

Phase 2 Recruiting

45 enrolled

Lymphoid

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06550141 2025-11-14

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Phase 2 Recruiting

28 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05794958 2025-09-23

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

Phase 1 Recruiting

20 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

Clinical Trials

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

PiNACLE-H2H

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

LATE-R-GEL-23

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel